Sellas Life Sciences Group Inc expected to post a loss of 8 cents a share - Earnings Preview

Sellas Life Sciences

09/08/2025 24:58

Sellas Life Sciences Group Inc SLS.OQ SLS.O is expected to  show no change in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Sellas Life Sciences Group Inc is for a loss of 8 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Sellas Life Sciences Group Inc is $7.00, about 77.4% above its last closing price of $1.58

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.10
-0.10
-0.07
Beat
33.3
Dec. 31 2025
-0.11
-0.11
-0.08
Beat
25.5
Sep. 30 2024
-0.14
-0.13
-0.10
Beat
23.1​
Jun. 30 2024
-0.17
-0.16
-0.13
Beat
21.2
​​Mar. 31 2024
-0.16
-0.16
-0.21
Missed
-31.2
Dec. 31 2023
-0.27
0.00
-0.25
Missed
-8,990.9​
Sep. 30 2023
0.03
0.03
-0.33
Missed
-1,200
Jun. 30 2023
-0.34
-0.35
-0.31
Beat
12.7

This summary was machine generated August 8 at 23:58 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)